Merck Presents Key Data on Vaccines and Infectious Disease Pipeline at IDWeek 2024

Merck, known as MSD outside the U.S. and Canada, announced it will present new research at IDWeek 2024 in Los Angeles from October 16-19, showcasing advancements in its vaccines and infectious disease portfolio and promising developments from its pipeline.

“The breadth of innovative research we will showcase during IDWeek 2024 is a testament to our ongoing commitment to advancing science to address persisting global health needs, such as RSV. We are proud of our company’s longstanding legacy and continued momentum in helping to treat and prevent a variety of potentially serious infectious diseases for individuals around the world and across all stages of life – from birth through older adulthood – and we look forward to sharing these data,” said Dr Paula Annunziato, senior vice president, infectious diseases and vaccines, Global Clinical Development, Merck Research Laboratories.

Highlights include detailed positive results from a Phase 2b/3 trial of clesrovimab (MK-1654), a monoclonal antibody aimed at preventing respiratory syncytial virus (RSV) in infants, and data from the Phase 3 STRIDE-8 trial evaluating CAPVAXIVE™, a pneumococcal vaccine for adults at higher risk of pneumococcal disease. Additionally, Merck will present Week 48 data from a Phase 2 study of a once-weekly oral regimen combining its islatravir with Gilead’s lenacapavir for HIV-1 treatment.

Key presentations will feature during IDWeek 2024:

- Phase 2b/3 trial results on clesrovimab in pre-term and full-term infants.

- Safety and efficacy comparison of clesrovimab versus palivizumab in high-risk infants.

- Phase 3 data from the STRIDE-8 trial on CAPVAXIVE in adults aged 18-64.

- Week 48 findings on islatravir plus lenacapavir for HIV-1 treatment.

- Insights from the SPECTRA study and the SMART surveillance program on antimicrobial resistance trends.